Abstract. Extracellular HMGB1 triggers inflammation following infection or injury, and supports tumorigenesis in inflammation-related malignancies. HMGB1 has several redox states: reduced HMGB1 recruits inflammatory cells to injured tissues forming a heterocomplex with CXCL12 and signaling via its receptor CXCR4; disulfide-containing HMGB1 binds to TLR4 and promotes inflammatory responses. Here we show that Diflunisal, an aspirin-like nonsteroidal anti-inflammatory drug (NSAID) that has been in clinical use for decades, specifically inhibits in vitro and in vivo the chemotactic activity of HMGB1 at nanomolar concentrations, at least in part by binding directly to both HMGB1 and CXCL12 and disrupting their heterocomplex. Importantly, Diflunisal does not inhibit TLR4-dependent responses. Our findings clarify the mode of action of Diflunisal, and open the way to the rational design of functionally specific anti-inflammatory drugs.
Introduction
High-Mobility Group Box-1 (HMGB1), a highly conserved and abundant nuclear protein expressed in all eukaryotic cells, is a key trigger of inflammation (Andersson & Tracey, 2011; Bianchi et al, 2017) . HMGB1 consists of two structurally independent L-shaped tandem HMG-box domains (~80 amino acids each), referred to as Box A and Box B, connected by a flexible linker and followed by a long acidic C-terminal tail of 30 amino acids (Thomas, 2001) . Within the nucleus, HMGB1 is a DNA chaperone that regulates nucleosome assembly and chromatin structure, promotes interactions between several transcription factors and facilitates their binding to DNA (Štros, 2010) . HMGB1 is passively released in the extracellular space by dead cells and is actively secreted by severely stressed cells (reviewed in Bianchi et al, 2017) . Extracellular HMGB1 alerts the host to unscheduled cell death, to stress, and to microbial invasion, thus playing a key role in inflammation and immune responses (Bianchi et al, 2017) . In particular, it triggers inflammation following injury or infection by first recruiting inflammatory cells (Schiraldi et al, 2012) and then activating them (Venereau et al, 2012) . HMGB1-induced recruitment of inflammatory cells depends on the formation of a heterocomplex with the chemokine CXCL12, which in turn activates CXCR4, a G-protein coupled receptor (Venereau et al, 2012) . Notably, the formation of a disulfide bond between cysteines 22 and 44 makes HMGB1 unable to form the heterocomplex, but makes it a ligand of TLR4, a receptor that also recognizes LPS (Venereau et al, 2012) . Since the two redox states of HMGB1 have alternative activities, it would be desirable to inhibit them selectively.
Interfering with the formation of the HMGB1-CXCL12 heterocomplex with small molecules is an attractive but challenging route, mainly because the large and flat interfaces typically associated with protein-protein interactions have reduced druggability (Laraia et al, 2015; Scott et al, 2016) . Here, we show that Diflunisal (DFL) (Fig. 1A) , an aspirin-like nonsteroidal anti-inflammatory drug that was identified in the 1970s through phenotypic screens (Steelman et al, 1978) , exerts its anti-inflammatory action at least in part by disrupting the interaction between HMGB1 and CXCL12.
Results and Discussion
We recently found that Salicylic Acid suppresses HMGB1's pro-inflammatory activity and inhibits HMGB1-induced motility, migration, invasion and anchorage-independent colony formation of mesothelioma cells via a cyclooxygenase-2-independent mechanism (Choi et al, 2015; Yang et al, 2015) . Aiming at finding more potent HMGB1 inhibitors, we tested DFL, another FDA-approved salicylate, using migration of mouse 3T3 fibroblasts as cellular readout (Fig. 1B) . DFL halved the number of migrating cells already at a concentration of 10 nM, the lowest documented IC 50 so far for HMGB1 inhibitors (Venereau et al, 2016) . Importantly, DFL did not affect chemotaxis toward fMLP (Fig. 1B) indicating that it does not influence the general mobility of fibroblasts.
We then asked whether DFL was a direct ligand of HMGB1. We performed NMR saturation transfer difference (STD) (Mayer & Meyer, 2001 ) and water-Ligand Observation via Gradient SpectroscopY (waterLOGSY) experiments (Dalvit et al, 2001) on DFL (1 mM) in the presence of sub-stoichiometric concentrations of recombinant HMGB1 (50 μM). We observed STD signals and inversion of the sign in waterLOGSY 4 spectra for all DFL protons to varying extents, thus demonstrating a direct DFL-HMGB1 interaction (Appendix Fig. S1 ). and Box B (right) (color, residues with CSP > avg + sd). HMGB1 residues (sticks) involved in hydrophobic and electrostatic interactions with DFL are explicitly labelled. E) DFL does not affect cell migration induced by fMLP nor by 1 nM R23AK27A HMGB1 mutant (compare to panel B). The data represent the avg ± sd of three replicates of one representative experiment. The difference in migration towards R23AK27A HMGB1 in the presence or absence of DFL is statistically non-significant (one-way ANOVA plus post tests). (Appendix Fig. S2 ). The pattern of chemical shift perturbations (CSPs) indicated that DFL binds to both boxes in full-length HMGB1 (Fig. 1C) . Indeed, residues whose amide resonances showed significant CSPs (CSP > avg + sd), i.e. Y15, A16, Q20, T21, R23, F40, S41, C44, S45 in Box A, and F102, F104, C105, R109, D123, V124, K140 in Box B, were similar to the ones mostly affected in DFL titrations into isolated HMG Boxes (Appendix Fig. S3 ). When mapped on the structure of the two HMG boxes, residues with significant CSP defined a surface located at the crux of the typical L-shaped fold, characterized by a small solventexposed hydrophobic surface suitable for favorable van der Waals (vdW) interactions with the aromatic rings of DFL (Fig. 1D ).
CSPs data were next used to generate HADDOCK (Dominguez et al, 2003) data-driven docking models of DFL in complex with Box A and Box B. The binding modes are highly reminiscent of the ones observed for Glycyrrhizin (Mollica et al, 2007) , a well-known HMGB1 inhibitor. DFL accommodates at the junction of the two arms of both individual HMG boxes, establishing favorable vdW interactions with the hydrophobic side chains of V19 and F37 in Box A and of V124 and L128 in Box B (Fig. 1D) . Additionally, the models predict stabilizing electrostatic interactions between DFL carboxylate and R23 and R109 sidechains (Fig. 1D) . To prove the role of electrostatic interactions in ligand binding, we took advantage of an HMGB1 mutant (R23AK27A) that was previously used to prove the binding of Salicylic Acid to the same interaction surface (Choi et al, 2015) . Indeed, NMR titration of DFL into 15 N labelled HMGB1 R23AK27A mutant induced significantly lower
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CSPs as compared to the ones observed for the wildtype protein (Appendix Fig. S4 ), indicative of a weaker binding. Accordingly, DFL was not effective on cell migration induced by the R23AK27A HMGB1 mutant (Fig. 1E ).
Microscale thermophoresis (MST) measurements (Wienken et al, 2010) , performed by titrating DFL into fluorescently labelled HMGB1, yielded an apparent dissociation constant (K d ) of 1.6 ± 0.8 mM (Appendix Fig. S5 ), in agreement with the fast-intermediate exchange regime observed in NMR titrations. However, such low affinity was in striking contrast with the high activity of DFL in cell migration experiments, thus arguing for a more complex inhibition mechanism than a conventional ligand-protein binary interaction.
We thus hypothesized that DFL might target the HMGB1/CXCL12 heterocomplex, rather than HMGB1 alone. To explore this possibility, we first investigated whether DFL could S6 ). The highest resonance shifts involved residues located on the β1 strand (V23, H25, K27) and residues (A40, N45, Q48, V49) around the so-called sY21 CXCR4 binding site (Veldkamp et al, 2006 (Veldkamp et al, , 2008 , which is recognized by the sulfated CXCR4 extracellular N-terminus ( Fig. 2A) . Prompted by this observation, we performed STD and waterLOGSY competition experiments between DFL and the CXCR4 1-38sY21 peptide that corresponds to the N-terminal tail of CXCR4 sulfated in position Y21 (Veldkamp et al, 2006 (Veldkamp et al, , 2008 . Reduction of DFL signal intensities in STD and waterLOGSY spectra upon addition of CXCR4 1-38sY21 indicated that both ligands compete for the same binding site (Fig. 2B) . 
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Ligands targeting the sY21 binding pocket are also known to allosterically trigger CXCL12 dimerization upon binding (Ziarek et al, 2013) . Thus, we hypothesized that CSPs involving the β1 strand ( Fig Cell migration experiments, however, showed that DFL was unable to inhibit CXCL12-induced chemotaxis at concentrations where it inhibited chemotaxis induced by HMGB1 (Fig. 2D) . Thus, neither binding to HMGB1 alone or CXCL12 alone can justify the inhibition of chemotaxis. However, DFL might also bind to and/or interfere with the HMGB1/CXCL12 heterocomplex. Indeed, DFL significantly reduced the migration of 3T3 fibroblasts chemotaxis towards the preformed HMGB1/CXCL12 heterocomplex (Fig. 2E ).
To verify biophysically that DFL interferes with the HMGB1/CXCL12 heterocomplex, we first produced the heterocomplex by titrating unlabeled CXCL12 (up to 0.2 mM) into 15 N labelled HMGB1 (0.1 mM) (Fig. 3A ,B top), and then added DFL (Fig. 3D ,E). As already reported (Schiraldi et al, 2012) , complex formation induced the reduction or fold and E) ten-fold excess of DFL. F) MST competition experiment: the heterocomplex is preformed using 50 nM and 50 M of HMGB1 and CXCL12, respectively, and measurements were performed in the presence of increasing concentrations of DFL. Decreasing MST signal (from 930 to 910 a.u.) upon DFL titration indicates that CXCL12 has been displaced from HMGB1. n=3; error bars represent ± sd. G) DFL does not inhibit chemotaxis towards 3S. 3T3 fibroblasts were subjected to chemotaxis assays in Boyden chambers; 1 nM fully reduced HMGB1 (green) or 3S (red), or no chemoattractant (black), were added in the lower chamber, together with 1 µg/ml of anti-CXCL12 monoclonal antibody or 30 nM DFL. The data represent the avg ± sd of four replicates. ***, p<0.001 relative to migration towards HMGB1, one-way (Fig. 3E , blue, Appendix Figure S9 ), indicating that CXCL12 was displaced and the heterocomplex disrupted. Notably, some HMGB1 cross-peaks were shifted with respect to free HMGB1 due to binding of DFL (Appendix Fig . S9 ). In MST experiments addition of increasing concentrations of DFL to a preformed HMGB1/CXCL12 complex lead to a sharp transition at 380 ± 17 M, consistent with the disassembly of fluorescently labelled HMGB1 from the heterocomplex (Fig. 3F ).
In line with the evidence that DFL affects the HMGB1/CXCL12 heterocomplex, we predicted that DFL would not affect the chemoattractant activity of 3S, a mutant of HMGB1 where all cysteines are replaced by serines. 3S has the same chemoattractant properties as HMGB1, but does not need to form a complex with CXCL12 (Tirone et al, 2018) . Indeed, both a monoclonal antibody against CXCL12 and DFL inhibited HMGB1-induced chemotaxis, but neither was effective on chemotaxis induced by 3S (Fig. 3G ).
HMGB1 containing a disulfide bond between cysteines 22 and 44 induces cytokine production by binding to receptor TLR4 (He et al, 2018) . Conversely, disulfide-containing HMGB1 cannot form a complex with CXCL12 (Schiraldi et al, 2012) . Thus, if DFL specifically targets the HMGB1/CXCL12 heterocomplex, it should not interfere with the transcription and release of pro-inflammatory cytokines specifically triggered by disulfide HMGB1. Indeed, addition of DFL did not affect the transcription of TNF in mouse macrophages stimulated with disulfide HMGB1 (Fig. 3H) ; likewise, DFL did not affect cytokine induction by disulfide HMGB1 in human macrophages (Appendix Fig. S10) . This is at variance with the effect of Salicylic Acid, an active metabolite of aspirin, which inhibits the cytokine-inducing activities of disulfide HMGB1 (Choi et al, 2015) .
Next, we tested in vivo the ability of DFL to inhibit the migration of inflammatory cells into injured muscle, which also depends on the HMGB1/CXCL12 heterocomplex (Tirone et al, 2018) . Muscle injury was induced by a single dose of cardiotoxin in the tibialis anterior muscle of C57Bl/6 wild type mice, and the infiltration of leukocytes (CD45+ cells) in injured muscle was assessed 6 hours later (Schiraldi et al, 2012) . DFL significantly decreased the recruitment of CD45+ cells into the injured muscle compared to vehicletreated mice (Fig. 3I) . As previously reported (Schiraldi et al, 2012) , Glycyrrihizin also inhibited recruitment of leukocytes into injured muscle (Fig. 3I) ; we thus tested whether its inhibitory activity was mechanistically similar to that of DFL. Indeed, NMR titration experiments clearly showed that Glycyrrhizin binds directly to CXCL12, affecting a binding surface similar to that targeted by DFL (Appendix Fig. S11 ). Most importantly, Glycyrrhizin was able to disrupt the HMGB1-CXCL12 complex, as shown in (Appendix Fig. S12 ). Of note, in strong analogy to DFL, Glycyrrhizin is not an inhibitor of CXCL12 induced chemotaxis (Schiraldi et al, 2012) .
Taken together, these data support a multi-step molecular mechanism whereby DFL and Glycyrrhizin inhibit the chemotactic activity of HMGB1 by targeting the HMGB1/CXCL12
heterocomplex. The unexpected combinatorial binding activity of HMGB1 inhibitors might in part reconcile the unusual differences observed between their inhibition activity and the affinities to their single targets. Herein, DFL appears to work as a multi-target drug (Bolognesi & Cavalli, 2016; Anighoro et al, 2014) , displaying a low affinity towards its multiple targets but resulting in high efficiency through their simultaneous engagement (Korcsmáros et al, 2007) .
Salicylates and their derivatives are potent and widely used anti-inflammatory drugs with a wide spectrum of modulating activities on cyclooxygenases (Warner et al, 1999) , NFkB (Kopp & Ghosh, 1994) , AMPK (Hawley et al, 2012) and CBP/p300 acetyltransferase activity (Shirakawa et al, 2016) . Results presented in this work add to the variety of mechanisms in which DFL is involved. Importantly, DFL has been and is widely employed, and the understanding of its mode of action can inform and improve its clinical usage. Notably, the use of DFL should be discouraged during the healing of damaged tissue, as we showed that the HMGB1/CXCL12 heterocomplex favors muscle, bone or liver regeneration after damage (Tirone et al, 2018) .
In conclusion, the ability of DFL to selectively interfere with the HMGB1/CXCL12 inflammatory axis through the simultaneous binding to both HMGB1 and CXCL12 offers unprecedented structural/functional insights into the anti-inflammatory activity of DFL as a NSAID. These insights also show that protein-protein interactions within the HMGB1-CXCL12 heterocomplex are druggable with high specificity and selectivity, thus opening new strategies for the rational design of novel inhibitors of this crucial inflammatory axis.
Materials and Methods
Recombinant HMGB1 constructs, including Box A (residues 1-89), Box B (residues 90-175), full-length HMGB1 (residues 1-214) were produced by expressing constructs in a C-labelled CXCL12 were provided by HMGBiotech (Milan, Italy). HMGB1 R23AK27A mutant was produced as described in (Choi et al, 2015) . For biophysical measurements, all HMGB1 constructs, after expression and purification, were dialyzed against NMR buffer, containing 20 mM phosphate buffer pH 7.3, 150 mM NaCl, 1 mM DTT. CXCL12 was dialyzed against a buffer containing 20 mM phosphate buffer pH 6, 20 mM NaCl.
Proteins concentrations were determined measuring the absorbance at 280 nm considering molar extinction coefficients of 9970, 10810, 21430 and 8700 M -1 cm -1 for Box A, Box B, HMGB1 and CXCL12, respectively.
Proteins used for cell-based and in vivo assays were provided by HMGBiotech (Milan).
Diflunisal (5-(2,4-difluorophenyl)-2-hydroxybenzoic acid) was purchased from SigmaAldrich.
Peptide synthesis and purification
The CXCR4 1-38sY21 peptide with sequence MEGIDIYTSDNYTEEMGSGDY(Sulfo)DSMKEPAFREENANFNK was synthesized using the Fmoc method (Fields & Noble, 1990 ) and purified by preparative reversed-phase chromatography (RP-HPLC). Details on peptide synthesis and purification are reported in Appendix.
NMR Measurements
NMR spectra were recorded at 298 K on a Bruker Avance 600 MHz spectrometer (Karlsruhe, Germany) equipped with a triple-resonance TCI cryoprobe with an x, y, zshielded pulsed-field gradient coil. Spectra were processed with Topspin mM NaCl) has been performed adding 0.25, 0.5, 1, 2 equivalents of ligand to the labelled proteins using a 10 mM stock solution (20 mM phosphate buffer, pH 7.3, 150 mM NaCl).
Saturation Transfer Difference and Water-ligand observed via gradient spectroscopy.
STD and waterLOGSY experiments have been performed on 0.5 mM DFL in the presence of 0.05 mM HMGB1 or CXCL12 in NMR buffer. STD experiments were acquired using a pulse scheme (Bruker pulse sequence: stddiffesgp.3) with excitation sculpting with gradients for water suppression and spin-lock field to suppress protein signals. The spectra were acquired using 128 scans, a spectral width of 9600 Hz, 64K data points for acquisition. For protein saturation, a train of 60 Gaussian shaped pulses of 50 ms was applied, for a total saturation time of 3 s. Relaxation delay was set to 3 s.
On-and off-resonance irradiations were set at 0 ppm and at 107 ppm, respectively. STD spectra were obtained by internal subtraction of the on-resonance spectrum from the offresonance spectrum.
WaterLOGSY experiments were acquired using a pulse scheme as described (Dalvit et al, 2000) with excitation sculpting and flip-back for water suppression. The spectra were acquired using 128 scans, 32K data points for acquisition, mixing time was set to 1 s.
Competition experiments have been performed comparing STD and waterLOGSY performed on 0.5 mM DFL with 0.05 mM CXCL12 and upon addition of 0.2 mM of CXCR4 1-38sY21 peptide.
Dissociation constant estimation:
The apparent dissociation constant between DFL and 15 N-CXCL12 was estimated from least-squares fitting of CSPs (9 residues) as a function of total DFL concentration according to the equation: N relaxation rates (R 1 , R 2 ) were measured using standard 2D methods (Farrow et al, 1994) . For R 1 and R 2 experiments a duty-cycle heating compensation was used (Yip & Zuiderweg, 2005) ; the two decay curves were sampled at 12 (ranging from 50 to 2000 ms) and 11 (from 12 to 244 ms) different time points, respectively. Both R 1 and R 2 experiments were collected in random order and using a recovery delay of 2.5 s. R 1 and R 2 values were fitted to a 2-parameter exponential decay from the intensities using the fitting routine implemented in the CcpNmr program; duplicate measurements were used to allow a statistical analysis of the uncertainties (Skelton et al, 1993) . HSQC spectra Only residues corresponding to non-overlapping peaks, with heteronuclear nOe > 0.65
were used, residues with anomalous R 2 were excluded (Barbato et al, 1992) .
Docking models
Molecular docking of DFL on Box A (residues G3-Y77), Box B (A93-G173) (coordinates were extracted from the PDB structure with code: 2YRQ) and CXCL12 (K1-K68, coordinates extracted from the PDB structure with code: 4UAI) were performed using the data-driven software HADDOCK 2.2 (Dominguez et al, 2003; van Zundert et al, 2016) following the classical three-stage procedure which includes: (1) randomization of orientations and rigid body minimization, (2) simulated annealing in torsion angle space, and (3) refinement in Cartesian space with explicit water. Ambiguous interaction restraints (AIRs) were defined as follows: residues with CSP > avg + sd or displaying intramolecular nOes were used to define active residues, whose solvent accessible surface neighbors were set as passive (Appendix Table S1 ). In the case of CXCL12, only the residues located around the sY21 binding site (violet CSP in Fig. 2D ) were set as active (Appendix Table S1 ), as STD competition experiments of DFL in the presence of CXCR4 1-38sY21 demonstrated that they both compete for the sY21 binding site. In the case of Box A (Box B), intermolecular nOes were included as unambiguous restraints in the calculations only in the semi-flexible refinement stage, setting the maximum distance of the nOe H pairs to 5 Å (Appendix Table S1 ).
Optimized parameters for liquid simulation (OPLS) were used for the protein (proteinallhdg5-4 and protein-allhdg5-4-caro). The geometric coordinates and parameters for DFL were calculated and optimized using the PRODRG server (Schüttelkopf & van Aalten, 2004) . Calculations generated 1000, 1000, 500 structures for the rigid body docking (it0), the semi-flexible refinement (it1) and the explicit solvent refinement (water), Fernández-Recio et al, 2004) and ambiguous interaction restraint energy term, which reflects the accordance of the model to the input restraints.
HADDOCK models were clustered (Daura et al, 1999) based on their interface root mean square deviation (rmsd), setting the cutoff and the minimum number of models in a cluster to 1.8 Å and 10 for the boxes, and 2.5 Å and 10 for CXCL12, respectively.
Proteins were aligned and fitted on the backbone of active residues reported in Table S1 .
The rmsd of DFL was calculated only on the heavy atoms of the entire scaffold.
To remove any bias of the cluster size on the cluster statistics, the final overall score of each cluster was calculated on the four lowest HADDOCK scores models in that cluster.
For each protein the cluster with the best fitting with respect to the experimentally-driven restraints (lowest number of violations) and the best HADDOCK score (cluster 1 for Box A, cluster 5 for Box B and CXCL12) was selected (Appendix Fig. S13, S14 and S15) .
The analysis of the docking calculations was performed applying in-house python and tcl scripts. Molecular images were generated by PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC.
MST experiments
MST experiments were performed at 24°C on a NanoTemper® Monolith NT.115 instrument with red filters, using 40% LED power and 60% MST power. All the experiments were carried out using 6His-tagged HMGB1, non-covalently labelled with the NT647 fluorescence dye (Bartoschik et al, 2018) . MST buffer contained 20 mM phosphate buffer pH 7.3, 150 mM NaCl, 0.05% Tween, 1 mM DTT.
For binding assays, 16-points titration series of DFL or CXCL12 were prepared, whereby the ligand dilutions were generated as a 1:2 dilution of the stock solution using MST buffer; a constant amount of labelled HMGB1 (50 nM) was added to all dilution steps. (Fig. 3C ). Attempts to reach saturation failed, as higher DFL concentrations (up to 5 mM) induced aggregation phenomena, as assessed by the bumpiness of the MST traces (data not shown).
For all MST experiments data points were the average of three measurements (error bars correspond to standard deviation). Data analyses were carried out using NanoTemper analysis software using the K d model fitting for the binding assays and Hill model for competition experiments.
Migration experiments
For fibroblast chemotaxis, modified Boyden chambers were used with filters (pore diameter 8 µm; Neuro Probe) coated with 50 µg/mL fibronectin (Roche). 50,000 cells in 200 µL were added to the upper chamber. Serum-free DMEM as negative control, HMGB1 and/or other molecules were added to the lower chamber at the indicated concentration, and then cells were left to migrate for 3 hours at 37°C. Cells were fixed with ethanol and stained with Giemsa Stain (Sigma), then non-migrating cells were removed with a cotton swab. All assays were done at least in triplicate. The migrated cells were acquired with Zeiss Imager M.2 microscope at 10x magnification, then evaluated with an automated counting program.
Assay for Cytokine Induction on mouse BMDMs
Bone Marrow Derived Macrophages (BMDMs) were obtained as described (Zhang et al, 2008) and stimulated as described in the legend to Fig. 3 . Total RNAs were isolated using the Illustra RNAspin Mini kit (GE Healthcare), and complementary DNAs (cDNAs)
were obtained by reverse transcription with oligo(dT) primers (Invitrogen, Carlsbad, CA, USA) and SuperScript II Reverse Transcriptase (Invitrogen) following the manufacturers'
instructions. Quantitative real-time PCR was performed using a LightCycler480 (Roche Molecular Diagnostics), in triplicates, using SYBR Green I master mix. The ΔCt method was used for quantification, and the -actin gene was used for normalization.
The sequence of the primers was 
In vivo injury model
To assess the initial leukocyte recruitment after muscle injury, mice were injected intravenously with 200 µg of DFL (Sigma Aldrich) or Glycyrrhizin (Acros Organics) 3 hours before muscle injection with 50 µL of 15 µM cardiotoxin (Latoxan). After 6 hours, the injured Tibialis Anterior muscles were collected and dissociated in RPMI 1640 containing 0.2% collagenase B (Roche Diagnostics) at 37°C for 1 hour. CD45 + cells were purified by magnetic cell sorting by using anti-CD45 beads (Miltenyi Biotec) according to the manufacturer's instructions and quantified by Countess (Invitrogen).
The Paper Explained
PROBLEM:
HMGB1 is a key molecule that both triggers and sustains inflammation following infection or injury, and is involved in a large number of inflammatory and autoimmune diseases, and in certain types of cancer. Thus, it is appealing to develop drugs that target HMGB1
specifically. Moreover, HMGB1 has two broad activities: inflammatory cell recruitment, and induction of chemokines and cytokines. Targeting one class of activities and not the other one is even more attractive.
RESULTS
In this work we show that Diflunisal (DFL), an aspirin-like nonsteroidal anti-inflammatory drug that has been extensively used for many decades under the commercial name of Dolobid, inhibits HMGB1 in vitro and in vivo and blocks the recruitment of inflammatory cells at low nanomolar concentrations. Importantly, DFL does not interfere with chemokine/cytokines induction.
We have also worked out the unusual mode of action of DFL. Recruitment of inflammatory cells is known to depend on the formation of a heterocomplex between HMGB1 and the chemokine CXCL12, which in turn activates CXCR4, a G-protein coupled receptor (GPCR). Using a variety of techniques, we show that DFL binds directly to both HMGB1 and CXCL12, and targets and disrupts the HMGB1-CXCL12 heterocomplex.
IMPACT:
We have thus at least partially clarified the mode of action of DFL. Notably, since we find that DFL targets the HMGB1-CXCL12 heterocomplex, we suggest that it should not be given to patients recovering from injury or trauma. Most importantly, our work shows that protein-protein interactions within the HMGB1-CXCL12 heterocomplex are druggable, thus opening new strategies for the rational design of novel inhibitors.
